Money in the bank is money in the bank for an early stage biotech company with several Phase 1 investigational trials in progress and no income to speak of. This will keeps the lights on for another quarter or two. Hopefully, data announcements when they come this year will allow more comprehensive financial arrangements to be made and under better terms.
Go Imugene!
Ann: Imugene Receives A$20 million for Convertible Notes Issuance, page-4
-
- There are more pages in this discussion • 104 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
27.0¢ |
Change
-0.010(3.57%) |
Mkt cap ! $77.89M | |||
| Open | High | Low | Value | Volume |
| 28.0¢ | 28.0¢ | 26.3¢ | $1.990M | 7.367M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20000 | 27.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 27.5¢ | 209631 | 9 |
View Market Depth
| Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
| IMU (ASX) Chart |